Haleon (HLN) Projected to Announce Quarterly Earnings on Thursday

Haleon (NYSE:HLN) is projected to post its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect the company to announce earnings of $0.2669 per share and revenue of $7.4341 billion for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:00 AM ET.

Haleon Price Performance

HLN stock opened at $9.95 on Tuesday. Haleon has a 1 year low of $8.65 and a 1 year high of $11.28. The firm has a market capitalization of $43.80 billion, a P/E ratio of 25.50, a P/E/G ratio of 2.26 and a beta of 0.13. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.92 and a quick ratio of 0.71. The business’s 50-day moving average is $9.37 and its two-hundred day moving average is $9.85.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on HLN. Zacks Research downgraded shares of Haleon from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 21st. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research note on Tuesday, June 30th. Rothschild & Co Redburn downgraded Haleon from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 16th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Haleon in a report on Thursday, April 30th. Finally, Wall Street Zen upgraded Haleon from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Haleon currently has an average rating of “Moderate Buy”.

Hedge Funds Weigh In On Haleon

A number of hedge funds and other institutional investors have recently bought and sold shares of HLN. Parkside Financial Bank & Trust increased its stake in Haleon by 101.3% in the 4th quarter. Parkside Financial Bank & Trust now owns 2,847 shares of the company’s stock valued at $29,000 after buying an additional 1,433 shares during the period. Geneos Wealth Management Inc. lifted its stake in shares of Haleon by 33.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after acquiring an additional 1,203 shares during the period. Caitong International Asset Management Co. Ltd lifted its stake in shares of Haleon by 428.1% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 6,321 shares of the company’s stock worth $57,000 after acquiring an additional 5,124 shares during the period. Cary Street Partners Financial LLC boosted its holdings in shares of Haleon by 20.1% in the second quarter. Cary Street Partners Financial LLC now owns 6,646 shares of the company’s stock valued at $69,000 after acquiring an additional 1,113 shares in the last quarter. Finally, McMillan Office Inc. purchased a new stake in shares of Haleon in the fourth quarter valued at about $92,000. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.